AbbVie’s Humira victories show US biosimilars have a mountain to climb
The drug maker’s secondary patent strategy is vindicated after it guarantees market exclusivity over the world’s best-selling drug following favourable settlement with final hold-out
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.